U.S. onlyEducational navigation. Verify coverage and assistance with the official insurer, program, or treatment site.

How do I get Carvykti through my insurance?

Carvykti · ciltacabtagene autoleucel · One-time autologous BCMA-directed CAR T-cell infusion

Carvykti is part of the Carvykti CAR T-cell therapy family.

BCMA-directed CAR T therapy for relapsed/refractory multiple myeloma. Coverage now reaches an earlier treatment setting than older CAR T pathways, making exact prior-line and lenalidomide-refractory criteria especially important.

No account, member ID, name, date of birth or email is needed. Your selections stay in this page session.

1
WHY IS THIS MEDICINE BEING GIVEN?

Choose the diagnosis / reason.

Coverage rules can change by diagnosis and sometimes by formulation.

FINANCIAL HELP

Find help with your out-of-pocket costs.

Use the official support program below to check savings, patient-assistance, or access options that may apply to you.

MyCARVYKTI patient support →
IF COVERAGE GETS STUCK

The medicine may be only part of the problem.

Use the playbook that matches what is blocking treatment, then verify the current rule with the insurer, program or treatment site.

Build a next-step plan →

Important

MedicineCostHelp is an educational navigation tool, not an insurer and not a coverage determination. Medical policies, billing codes, product preferences and benefit placement can change. Sources were reviewed 2026-08-20. Verify the current official source before acting.

Search another expensive medicine →